Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/News Feed/Medtronic outperforms Else Nutrn in revenue, profitability, and analyst ratings, making it the stronger medical stock.
MDT
$80.48
+$0.01 +0.01%

Medtronic outperforms Else Nutrn in revenue, profitability, and analyst ratings, making it the stronger medical stock.

Market News
23 Mar 2026
Defense World
View Source
Neutral
pluang ai news

Medtronic significantly surpasses Else Nutrn in financial metrics, including $33.54 billion revenue versus $5.82 million, positive net income of $4.66 billion compared to Else Nutrn's $11.08 million loss, and stronger profitability ratios. Analysts favor Medtronic with a consensus price target suggesting a 28% upside and multiple buy/hold ratings, while Else Nutrn has no current analyst recommendations. Medtronic also shows lower stock volatility and higher institutional ownership, indicating greater market confidence. This comparison highlights Medtronic as the more stable and promising investment in the medical sector.

More News (MDT)

Global blood glucose monitoring market to nearly double to $39.4B by 2035 with 8.9% CAGR driven by AI and home care trends

Global blood glucose monitoring market to nearly double to $39.4B by 2035 with 8.9% CAGR driven by AI and home care trends

The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...

Market News
Bullish
2 days ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App